Stop comparing SZLS to EXASThis is how you know most of these guys that just spew prices and projections on here are just plain dumb or wishful gamblers.
Its simple. I do not care if SZLS claims to have a product that can test 10 cancers. The 2 companies are not comparable.
1. Management team: Read up about the Management team of EXAS. It is like day and light when compared with SZLS. Tripp cannot raise 1/10 of what those guys raised in the market. He lacks the technical know how.
2. EXAS's cologuard had its first fda approval in 2014. Aristotle has none and there is nothing in the works towards that. For a product like this to hit the main market, FDA approval is key.
Always do DD and think before posting senseless SPs. At best, this product will hit a few local laboratories. Price may double or triple from here at the most and then fall. Oh wait, thats if the Q1 release is real.